Latest Patient Access News

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.